A. Van Oosterom

732 total citations
28 papers, 572 citations indexed

About

A. Van Oosterom is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Molecular Biology. According to data from OpenAlex, A. Van Oosterom has authored 28 papers receiving a total of 572 indexed citations (citations by other indexed papers that have themselves been cited), including 14 papers in Oncology, 12 papers in Pulmonary and Respiratory Medicine and 7 papers in Molecular Biology. Recurrent topics in A. Van Oosterom's work include Sarcoma Diagnosis and Treatment (7 papers), Testicular diseases and treatments (4 papers) and Cancer Treatment and Pharmacology (4 papers). A. Van Oosterom is often cited by papers focused on Sarcoma Diagnosis and Treatment (7 papers), Testicular diseases and treatments (4 papers) and Cancer Treatment and Pharmacology (4 papers). A. Van Oosterom collaborates with scholars based in Belgium, Netherlands and Italy. A. Van Oosterom's co-authors include Maria Dêbiec‐Rychter, Guy Debrock, Raymond Oyen, Raf Sciot, Jaap Verweij, PHM de Mulder, Yves Humblet, E. Van Marck, Martine Berlière and Véronique D’Hondt and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Clinical Cancer Research.

In The Last Decade

A. Van Oosterom

27 papers receiving 549 citations

Peers

A. Van Oosterom

ONCOL

PRM

HEMAT

Reinhilde Weytjens Belgium

P. Huget Belgium

Daniel Buergy Germany

Elisa Zanardi Italy

Sasja F. Mulder Netherlands

A. McDonald United Kingdom

Jeff White United Kingdom

Seizo Masutani Japan

Anwar Tarabichi Germany

Justine Hollyer United Kingdom

Reinhilde Weytjens Belgium

A. Van Oosterom

337 ×1.3

ONCOL

254 ×1.1

161 ×0.8

PRM

143 ×1.2

97 ×1.3

HEMAT

Citations per year, relative to A. Van Oosterom A. Van Oosterom (= 1×) peers Reinhilde Weytjens

Countries citing papers authored by A. Van Oosterom

Since Specialization

Citations

This map shows the geographic impact of A. Van Oosterom's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by A. Van Oosterom with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites A. Van Oosterom more than expected).

Fields of papers citing papers by A. Van Oosterom

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by A. Van Oosterom. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by A. Van Oosterom. The network helps show where A. Van Oosterom may publish in the future.

Co-authorship network of co-authors of A. Van Oosterom

This figure shows the co-authorship network connecting the top 25 collaborators of A. Van Oosterom. A scholar is included among the top collaborators of A. Van Oosterom based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with A. Van Oosterom. A. Van Oosterom is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Schuetze, S M, Piotr Rutkowski, Maria Dêbiec‐Rychter, et al.. (2009). Combined analysis of the EORTC and SWOG phase II trials of imatinib in advanced dermatofibrosarcoma protuberans (DFSP). Journal of Clinical Oncology. 27. 3 indexed citations

Blay, Jean‐Yves, Axel Le Cesne, Jeremy Whelan, et al.. (2006). Gefitinib in second line treatment of metastatic or locally advanced synovial sarcoma expressing HER1: A phase II trial of EORTC Soft Tissue and Bone Sarcoma Group. Journal of Clinical Oncology. 24(18_suppl). 9517–9517. 7 indexed citations

Tabernero, Josep, Patrick Schöffski, Federico Rojo, et al.. (2005). Combined anti-EGFR blockade: A phase I pharmacokinetic and molecular pharmacodynamic study of Cetuximab (Erbitux (R)) and Gefitinib (Iressa (R)) in patients with advanced colorectal, head and neck and non-small cell lung cancer expressing the EGFR. Clinical Cancer Research. 11(24). 4 indexed citations

Ghysel, Christophe, et al.. (2003). A lymph node metastasis from a ‘burned‐out’ germ cell tumour presenting as an inguinal mass. British Journal of Urology. 92(s3). e2–e2. 1 indexed citations

Debrock, Guy, et al.. (2003). A phase II trial with rosiglitazone in liposarcoma patients. British Journal of Cancer. 89(8). 1409–1412. 131 indexed citations

Dumez, Herlinde, Marloes Louwerens, A.S.T. Planting, et al.. (2002). The impact of drug administration sequence and pharmacokinetic interaction in a phase I study of the combination of docetaxel and gemcitabine in patients with advanced solid tumors. Anti-Cancer Drugs. 13(6). 583–593. 22 indexed citations

Roeyen, Geert, Paul Van Schil, Johan Somville, Cécile Colpaert, & A. Van Oosterom. (1999). Chordoma of the mediastinum.. PubMed. 25(2). 224–5. 4 indexed citations

Droz, J.P., A.-R. Hanauske, Jaap Verweij, et al.. (1998). Broad phase II and pharmacokinetic study of methoxy-morpholino doxorubicin (FCE 23762-MMRDX) in non-small-cell lung cancer, renal cancer and other solid tumour patients. British Journal of Cancer. 77(1). 139–146. 13 indexed citations

Wit, Ronald de, Laurence Collette, Richard Sylvester, et al.. (1998). Serum alpha-fetoprotein surge after the initiation of chemotherapy for non-seminomatous testicular cancer has an adverse prognostic significance. British Journal of Cancer. 78(10). 1350–1355. 26 indexed citations

10.

Bontenbal, M., Maria Andersson, J. Wildiers, et al.. (1998). Doxorubicin vs epirubicin, report of a second-line randomized phase II/III study in advanced breast cancer. British Journal of Cancer. 77(12). 2257–2263. 41 indexed citations

11.

Tueni, Elias, A. Van Oosterom, Ad Backx, et al.. (1997). Phase IB study of doxorubicin in combination with the multidrug resistance reversing agent S9788 in advanced colorectal and renal cell cancer. British Journal of Cancer. 76(10). 1376–1381. 16 indexed citations

12.

Laer, Carl Van, Evert Hamans, I. Neetens, et al.. (1996). Benign fibrous histiocytoma of the larynx: presentation of a case and review of the literature. The Journal of Laryngology & Otology. 110(5). 474–477. 8 indexed citations

13.

Mulder, PHM de, G.O.N. Oosterhof, C Bouffioux, et al.. (1995). EORTC (30885) randomised phase III study with recombinant interferon alpha and recombinant interferon alpha and gamma in patients with advanced renal cell carcinoma. British Journal of Cancer. 71(2). 371–375. 46 indexed citations

14.

Vermeulen, P., Didier Verhoeven, Guy Hubens, et al.. (1995). Microvessel quantification in primary colorectal carcinoma: an immunohistochemical study. British Journal of Cancer. 71(2). 340–343. 67 indexed citations

15.

D’Hondt, Véronique, Yves Humblet, T. Guillaume, et al.. (1995). Thrombopoietic effects and toxicity of interleukin-6 in patients with ovarian cancer before and after chemotherapy: a multicentric placebo- controlled, randomized phase Ib study. Blood. 85(9). 2347–2353. 72 indexed citations

16.

Oosterom, A. Van, et al.. (1994). N-ras & c-myc expression induces cddp resistance in human melanoma cell lines. European Journal of Cancer. 30. S5–S5.

17.

Schil, Paul Van, et al.. (1993). Primary Mediastinal Leiomyosarcoma. The Thoracic and Cardiovascular Surgeon. 41(6). 377–378. 6 indexed citations

18.

Verweij, Jaco J., M. Clavel, G. Catimel, et al.. (1993). Phase II study with taxotere(RP56976) in advanced soft tissue sarcomas of the adult. European Journal of Cancer. 29. S183–S183. 5 indexed citations

19.

Vantongelen, K., William P. Steward, G. Blackledge, Jaap Verweij, & A. Van Oosterom. (1991). EORTC joint ventures in quality control: Treatment-related variables and data acquisition in chemotherapy trials. European Journal of Cancer and Clinical Oncology. 27(2). 201–207. 33 indexed citations

20.

Wouters, E., Jan P. van Meerbeeck, Luc Dirix, et al.. (1991). Disseminated lung cancer or extragonadal germ cell tumour?. European Respiratory Journal. 4(1). 84–87. 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact